SG10201913959WA - Anti-kras-g12d t cell receptors - Google Patents

Anti-kras-g12d t cell receptors

Info

Publication number
SG10201913959WA
SG10201913959WA SG10201913959WA SG10201913959WA SG10201913959WA SG 10201913959W A SG10201913959W A SG 10201913959WA SG 10201913959W A SG10201913959W A SG 10201913959WA SG 10201913959W A SG10201913959W A SG 10201913959WA SG 10201913959W A SG10201913959W A SG 10201913959WA
Authority
SG
Singapore
Prior art keywords
kras
cell receptors
receptors
cell
Prior art date
Application number
SG10201913959WA
Other languages
English (en)
Inventor
Eric Tran
Yong-Chen Lu
Anna Pasetto
Paul F Robbins
Steven A Rosenberg
Zhili Zheng
Original Assignee
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By The Secretary filed Critical The United States Of America As Represented By The Secretary
Publication of SG10201913959WA publication Critical patent/SG10201913959WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
SG10201913959WA 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors SG10201913959WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662369883P 2016-08-02 2016-08-02

Publications (1)

Publication Number Publication Date
SG10201913959WA true SG10201913959WA (en) 2020-03-30

Family

ID=59564253

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913959WA SG10201913959WA (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors
SG11201900654QA SG11201900654QA (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201900654QA SG11201900654QA (en) 2016-08-02 2017-07-31 Anti-kras-g12d t cell receptors

Country Status (20)

Country Link
US (6) US10611816B2 (https=)
EP (2) EP3494133B1 (https=)
JP (4) JP6993402B2 (https=)
KR (1) KR102527052B1 (https=)
CN (2) CN109790211B (https=)
AU (3) AU2017306038B2 (https=)
CY (1) CY1125601T1 (https=)
DK (1) DK3494133T3 (https=)
ES (1) ES2928051T3 (https=)
HR (1) HRP20221183T1 (https=)
HU (1) HUE060121T2 (https=)
IL (2) IL264425B2 (https=)
LT (1) LT3494133T (https=)
PL (1) PL3494133T3 (https=)
PT (1) PT3494133T (https=)
RS (1) RS63615B1 (https=)
SG (2) SG10201913959WA (https=)
SI (1) SI3494133T1 (https=)
SM (1) SMT202200379T1 (https=)
WO (1) WO2018026691A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221183T1 (hr) * 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
KR20250037592A (ko) 2017-09-20 2025-03-17 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체
AU2018345400B2 (en) 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
CN114026116A (zh) * 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术(广东)有限公司 一种识别Kras G12V的高亲和力TCR
CN115151274B (zh) * 2019-11-05 2026-03-27 得克萨斯州大学系统董事会 Hla限制性hormad1 t细胞受体及其用途
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
KR102842684B1 (ko) * 2019-12-30 2025-08-05 브리스타 이뮤노테크 리미티드 향상된 t-세포 수용체 star 및 이의 적용
US20240294598A1 (en) * 2020-05-25 2024-09-05 China Immunotech (Beijing) Biotechnology Co., Ltd Enhanced synthetic t-cell receptor and antigen receptor
EP4178976A1 (en) * 2020-07-13 2023-05-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii?restricted drb t cell receptors against ras with g12d mutation
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
EP4247401A4 (en) * 2020-11-20 2025-06-11 Think Therapeutics, Inc. COMPOSITIONS AND METHODS FOR OPTIMIZED PEPTIDE VACCINES
WO2022115641A2 (en) * 2020-11-25 2022-06-02 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114920823B (zh) * 2022-05-27 2023-10-17 重庆医科大学 Tcr或其抗原结合片段及其应用
US20260021183A1 (en) * 2022-07-22 2026-01-22 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN115850444B (zh) * 2022-09-15 2025-01-28 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117777270B (zh) * 2022-09-29 2025-04-25 广州医科大学 一种t细胞受体(tcr)及其用途
CN120693174A (zh) * 2022-12-13 2025-09-23 百欧恩泰美国公司 T细胞受体构建体及其用途
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
WO2025259799A2 (en) * 2024-06-12 2025-12-18 Biontech Us Inc. T cell receptor compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US20020150891A1 (en) * 1994-09-19 2002-10-17 Leroy E. Hood Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
WO2008089053A2 (en) 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2012309830B2 (en) 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
WO2013081188A1 (ja) * 2011-11-30 2013-06-06 独立行政法人国立がん研究センター 誘導悪性幹細胞
TN2015000444A1 (en) * 2013-06-03 2017-04-06 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
GB201314404D0 (en) 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
CN118994363A (zh) 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
HRP20221183T1 (hr) * 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d
AU2024309123A1 (en) 2023-06-28 2026-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation

Also Published As

Publication number Publication date
CY1125601T1 (el) 2026-02-25
AU2023233125B2 (en) 2025-10-16
EP4159751A1 (en) 2023-04-05
CN118063591A (zh) 2024-05-24
PL3494133T3 (pl) 2022-11-21
JP2019527555A (ja) 2019-10-03
AU2026200276A1 (en) 2026-02-19
US20220089677A1 (en) 2022-03-24
JP2022050400A (ja) 2022-03-30
IL301894B2 (en) 2025-02-01
SI3494133T1 (sl) 2022-11-30
DK3494133T3 (da) 2022-09-19
AU2017306038A1 (en) 2019-02-14
WO2018026691A1 (en) 2018-02-08
US11208456B2 (en) 2021-12-28
US20210300988A1 (en) 2021-09-30
PT3494133T (pt) 2022-09-28
JP7413338B2 (ja) 2024-01-15
US20190177395A1 (en) 2019-06-13
IL301894B1 (en) 2024-10-01
IL264425A (https=) 2019-03-31
SMT202200379T1 (it) 2022-11-18
CN109790211B (zh) 2024-03-26
US11897933B2 (en) 2024-02-13
LT3494133T (lt) 2022-12-12
RS63615B1 (sr) 2022-10-31
US10611816B2 (en) 2020-04-07
SG11201900654QA (en) 2019-02-27
HUE060121T2 (hu) 2023-01-28
US11840561B2 (en) 2023-12-12
ES2928051T3 (es) 2022-11-15
JP2025090690A (ja) 2025-06-17
IL301894A (en) 2023-06-01
JP6993402B2 (ja) 2022-02-03
AU2017306038B2 (en) 2023-06-22
JP7649370B2 (ja) 2025-03-19
AU2023233125A1 (en) 2023-10-12
CN109790211A (zh) 2019-05-21
US20250340611A1 (en) 2025-11-06
CA3032870A1 (en) 2018-02-08
HRP20221183T1 (hr) 2022-12-09
EP3494133A1 (en) 2019-06-12
US20240209059A1 (en) 2024-06-27
EP3494133B1 (en) 2022-07-06
IL264425B2 (en) 2023-09-01
KR20190064566A (ko) 2019-06-10
US12391742B2 (en) 2025-08-19
US20200247869A1 (en) 2020-08-06
IL264425B1 (en) 2023-05-01
JP2024045139A (ja) 2024-04-02
KR102527052B1 (ko) 2023-04-27

Similar Documents

Publication Publication Date Title
IL264425B1 (en) t cell receptors against kras-g20
ZA201806866B (en) T cell receptors
ZA201806862B (en) T cell receptors
ZA201806865B (en) T cell receptors
IL262144A (en) t cell receptors
LT4219542T (lt) T ląstelių receptoriai
ZA201701823B (en) T cell receptors
GB201522592D0 (en) T cell receptors
SG10201913978RA (en) Anti-mutated kras t cell receptors
SG11201708313QA (en) T cell receptor
HUE064591T2 (hu) T-sejt receptorok
GB201603372D0 (en) Cell
PL3529267T3 (pl) Receptor komórek t
GB201609604D0 (en) Cell
HK40089237A (en) Anti-kras-g12d t cell receptors
GB201518991D0 (en) T cell receptors
HK1238270A1 (en) T cell receptors